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Abstract
Parkinson’s disease (PD) is histologically well defined by its characteristic degeneration of dopaminergic neurons in
the substantia nigra pars compacta. Remarkably, divergent PD-related mutations can generate comparable brain
region specific pathologies. This indicates that some intrinsic region-specificity respecting differential neuron
vulnerability exists, which codetermines the disease progression. To gain insight into the pathomechanism of PD,
we investigated protein expression and protein oxidation patterns of three different brain regions in a PD mouse
model, the PINK1 knockout mice (PINK1-KO), in comparison to wild type control mice. The dysfunction of PINK1
presumably affects mitochondrial turnover by disturbing mitochondrial autophagic pathways. The three brain
regions investigated are the midbrain, which is the location of substantia nigra; striatum, the major efferent region
of substantia nigra; and cerebral cortex, which is more distal to PD pathology. In all three regions, mitochondrial
proteins responsible for energy metabolism and membrane potential were significantly altered in the PINK1-KO
mice, but with very different region specific accents in terms of up/down-regulations. This suggests that disturbed
mitophagy presumably induced by PINK1 knockout has heterogeneous impacts on different brain regions.
Specifically, the midbrain tissue seems to be most severely hit by defective mitochondrial turnover, whereas cortex
and striatum could compensate for mitophagy nonfunction by feedback stimulation of other catabolic programs.
In addition, cerebral cortex tissues showed the mildest level of protein oxidation in both PINK1-KO and wild type
mice, indicating either a better oxidative protection or less reactive oxygen species (ROS) pressure in this brain
region. Ultra-structural histological examination in normal mouse brain revealed higher incidences of mitophagy
vacuoles in cerebral cortex than in striatum and substantia nigra. Taken together, the delicate balance between
oxidative protection and mitophagy capacity in different brain regions could contribute to brain region-specific
pathological patterns in PD.
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1 Introduction
Parkinson’s disease (PD) is one of the most common
neurodegenerative disorders in the elderly [1]. Approxi-
mately 4% of the population beyond age 65 years is
affected by PD. An important clinical symptom of PD is
impaired motor function manifested by resting tremor,
rigidity, bradykinesia and postural instability [2]. One
hallmark of PD is the selective degeneration of dopami-
nergic neurons in the substantia nigra pars compacta,
one of the most important dopaminergic brain regions.
Other brain regions, for instance cerebral cortex, are only
affected in much advanced disease stages [3].
Although over 95% of the PD cases lack clear familial
background [4], several recessive genetic mutations
showing Mendelian inheritance pattern can lead to famil-
ial PD cases that demonstrate significant clinical overlaps
with sporadic PD [5,6]. Such genetic hotspots include
PARK2 (Parkin), PINK1, DJ-1, UCHL1, LRRK2 (leucine-
rich repeat kinase 2) and PARK1 (alpha-synuclein) [4].
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generate rather indistinguishable PD pathology respect-
ing brain region specific neuron loss. Moreover, several
oxidative stress inducers such as MPTP (1-Methyl-4-phe-
nyl-1, 2, 3, 6-tetrahydropyridin), 6-hydroxydopamine (6-
OHDA) or paraquat, can faithfully reproduce comparable
neuronal death pattern similar to that observed in PD
[7-9]. This indicates that some intrinsic brain structural
dynamics set the tune in PD progression.
Different hypotheses exist regarding this selective cell
loss in PD, which refer to region specific neurotransmitter
synthesis, neuromelanin formation or the divergent pre-
sence of neurotoxic substances [10,11]. Recently, it has
become clear that mitochondrial dysfunction and oxidative
damage represent a convergence point for PD and other
neurodegenerative conditions [12]. In this respect, muta-
tions in two familiar PD related genes, PARK2 (encoding
Parkin) and PINK1 are both involved in the mitochondrial
quality control machinery termed mitochondrial autop-
hagy (also called mitophagy) [4,13]. However, this makes
even more peculiar why such ubiquitously present muta-
tions can lead to PD-specific selective neuron loss.
Based on the rationale that brain region specificity could
be intensively monitored via differential protein expression
profiles, we conducted an in-depth proteomic study in a
PD mouse model, the PINK1 knockout mice (PINK1-KO)
[4,14,15]. Our aim was to clarify the mechanism underly-
ing the PD brain region specificity. PINK1, or PTEN-
induced kinase 1, encodes a mitochondrial located kinase,
the mutation of which shows high penetrance to early-
onset PD [16-18]. Recently, its mode-of-action was eluci-
dated in its involvement of mitophagy [19,20]. In our pre-
vious communication, we showed that the loss-of-function
mutation of PINK1 leads to brain mitochondrial dysfunc-
tion and heightened susceptibility of neurons to oxidative
stress [21]. Here, we analyzed the PINK1-KO mouse
model by a two-dimensional difference gel electrophoresis
(2D-DIGE) based approach to determine protein expres-
sion alterations in three distinct brain regions: the mid-
brain, which is the location of substantia nigra,t h e
striatum, which is the major efferent region of substantia
nigra, and the cerebral cortex, which is more distal, and
thus less relevant to PD pathology. In addition, we used an
immunostaining methodology to investigate the protein
oxidation profiles in these different brain regions. Our
results suggest that possibly, the differential mitophagy
and oxidative protection capacity in different brain regions
could contribute to region-specific neuronal death pat-
terns in PD pathology.
2 Materials and methods
2.1 Animals and tissue samples
Animal experiments were carried out in accordance with
the USA community guidelines and were approved by
Harvard University Animal Care Committees. All efforts
were made to minimize animal suffering and to reduce
the number of animals used. Four-months-old PINK1-
KO mice of 129Sv background (n = 6) and their wild
type littermates (n = 6) were used for proteomic analyse
(2D-DIGE and Oxyblot). Three additional wild type mice
were used for electron microscopic investigations. For
the generation of PINK-KO mice, PINK-KO embryonic
stem cells were injected into blastocytes of C57BL/6
mice. Chimeric mice obtained were intercrossed with
(129/Sv × C57BL/6)F1 hybrid mice to acquire heterozy-
gous mutant mice, which were then intercrossed to
obtain homozygous mutant mice of 129Sv background.
These obtained PINK1
-/- mice (termed PINK-KO in the
manuscript) were kept in the 129/Sv background. The
ventral midbrain and the dorsal striatum tissues were dis-
sected out surgically. After removing brain stem and cer-
ebellum of the brain, we used the remaining portion
(forebrain) as cortex samples.
2.2 Sample preparation for two-dimensional
electrophoresis
Total protein extracts of mouse striatum, midbrain and
cortex tissues were prepared for each sample separately as
described previously [22]. Briefly, about 25 mg of the tis-
sue was ground in an Eppendorf tube submersed in liquid
nitrogen, adding 1.8 parts (v/w) of 50 mM Tris buffer (pH
7.5) containing 50 mM KCl, 20% (v/v) glycerol, 4% (w/v)
3-[(3-cholamidopropyl) dimethyl-ammonio]-1-propane
sulfonate (CHAPS), a phosphatase inhibitor mixture
(PhosStop, Roche, 04906845001) and a protease inhibitor
cocktail (Complete™, applied according to manufacturers
instruction, Roche, 11697498001). Finally, glass beads (1.5-
1.7 mm diameter, Wolf Glaskugeln GmbH) equivalent to
0.034 times of sample weight were added to the mixture
and samples were sonicated six times (20 seconds each,
1 minute interval under stirring) in an ice-water bath
(0°C). The resulting tissue homogenate was stirred for 30
minutes at 4°C after adding 0.025 parts (v/v) Benzonase
(Novagen, 70746). Subsequently, 6.5 mol/L urea and
2 mol/L thiourea were added to the sample. Protein con-
centration was determined using the Roti-Nanoquant Kit
(Roth, K880.1). Samples were stored at -80°C until subse-
quent analysis.
2.3 Two dimensional difference gel electrophoresis
(2D-DIGE) and protein expression pattern evaluation
80 μg protein of experimental (wild type control or
PINK1-KO) and the pooled reference samples were
labeled with fluorescence dye Cy5 or Cy3, respectively,
according to the manufacturer instructions (CyDye DIGE
Flours minimal dyes, GE Healthcare, 25-8008-61 and 25-
8008-62). As an internal standard for the DIGE quantifi-
cation system, the pooled reference sample consists of
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PINK1-KO mouse midbrain samples [23]. Proteins were
separated by 2D-DIGE as described previously [22,24]. In
short, capillary tube gels (40 cm in length, 1.5 mm dia-
meter) for isoelectric focussing were prepared with a spe-
cial mixture of carrier ampholytes covering a pH range of
3.5 to 9.5. The SDS-PAGE gel format was 40 cm × 30
cm. The gels were scanned using a Typhoon 9400 laser
scanner (GE Healthcare). Image analysis was performed
with the Delta2D software (version 3.4 and 4.0, DECO-
DON). 16 bit grey scale images were imported into the
program. Delta2D contains a special feature to handle
DIGE experiments which considers the reference data for
protein concentration normalization and quantification.
A fusion image over the whole experiment was generated
and employed for spot detection. After manual spot edit-
ing to eliminate inaccurate spots, the spot pattern was
transferred to all gel images within the project. The signal
intensities of each spot were computed as a weighted
sum of all pixel intensities ("volume” of protein spot).
The total pixel amount of all detected spots on the par-
ental gels was taken as 100%. This allows the software to
deduce the relative spot intensity of each individual spot
as percentage. In turn, this relative spot intensity data,
which are a quasi-linear correlates to protein concentra-
tion, were used to access the protein expression altera-
tions in PINK1-KO mouse. Here, over ninety-five
percent of the protein spots on the 2D gels that did not
vary in their spot intensity served as reference for nor-
malization. Normalized values after local background
subtraction were subsequently exported from Delta2D in
spreadsheet format. Unpaired Student’sT - T e s t sw e r e
used to determine significant protein spot differences
between the PD mouse model and controls (p < 0.05).
False discovery rate (FDR) of less than 5% was controlled
using the Delta2D software in-build permutation based
statistics. Only expression changes over 20% were consid-
ered for further analysis.
2.4 Protein identification by mass spectrometry
Database-assisted protein identification using mass spec-
trometry observed the up-to-date guidelines [25]. 500 μg
protein extract from each brain region was used as
described previously [26]. Briefly, proteins were separated
by two-dimensional protein electrophoresis and visua-
lized using a MS-compatible silver staining protocol [27].
Protein spots-of-interest were excised from the 2DE gel
and in-gel trypsin digestion was performed. Tryptic frag-
ments were analyzed either by a Reflex IV MALDI-TOF
mass spectrometer (Bruker Daltonics) or LCQ Deca XP
nanoHPLC/ESI ion trap mass spectrometer (Thermo
Fisher Scientific). Mass spectra were analyzed using in-
house licensed Mascot software (version 2.1, Matrix
Science) by automatic searches in NCBI non-redundant
databases restricted to taxonomy Mus musculus.S e a r c h
parameters allowed for one miscleavage and oxidation of
methionine and propionamidation of cysteine. Criteria
for positive identification of proteins with mass spectro-
metry were set according to the probability based Mowse
score algorithm (p ≤ 0.05) [28]. For protein identification
using ESI-MS/MS, a minimum of two peptides was
set as an additional criterion of successful protein
identification.
2.5 Protein functional categorization
In order to investigate the functional impact of protein
expression alterations induced by PINK1 knockout,
variant proteins detected in this study were subjected to
functional characterization with the help of public data-
bases. This includes Mouse Genome Informatics (MGI)
and Webgestalt http://bioinfo.vanderbilt.edu/webgestalt/,
which conduct gene set enrichment analyses by cross-
referencing downstream public databases including Gene
Ontology (GO, http://www.geneontology.org/) and Kyoto
Encyclopedia of Genes and Genomes (KEGG, http://
www.genome.jp/kegg/). Hereby, the entire mouse (Mus
musculus) proteins were used as a reference set. To
ensure the statistical significance of the enrichment ana-
lysis, the hypergeometric test was used with the statistical
threshold p < 0.0001, while the Bonferroni-Holm method
served as the multiple test adjustment control. The
adjusted p-values were reported in the result section, as
these are more stringent compared to the raw p-values.
A minimum of three genes was set as an additional cut-
off for the enrichment analyses.
2.6 Immunostaining for oxidized proteins (Oxyblot)
Oxidized proteins were detected by specific antibody
against protein carbonyl moieties on protein side chains
after Western blotting. For this purpose, precisely 100 μg
protein extract each were used from pooled controls (n =
6) and pooled transgenic samples (n = 6) of midbrain, stria-
tum or cortex. Experiments were repeated three times with
identical treatment. This constitutes a basis for the subse-
quent quantification procedure of the oxidized proteins.
Samples were first separated by 2DE with the gel for-
mat 16 cm (isoelectric focusing) × 12 cm (SDS-PAGE)
[22,29]. Subsequently, the proteins were transferred to a
PVDF-membrane (Millipore, IPVH00010) using the
Trans-Blot
® SD semi-dry electrophoretic transfer cell
(100 mA, 150 min, Bio-Rad). The membranes were
blocked overnight at 4°C with 5% skim dry milk solution
in TBST buffer (containing 0.1% Tween 20) under mild
agitation. The Oxyblot immunostaining was performed
according to the manufacture’s instruction (OxyBlot™
Protein Oxidation Detection Kit, Millipore, S7150). In an
incubation step, carbonyl groups on the protein side
chains were subjected to a condensation reaction with 2,
4-dinitrophenylhydrazine to yield 2, 4-dinitrophenylhy-
drazone (DNP-hydrazone). Subsequently, oxidized
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to the DNP-hydrazone moieties of the proteins. For che-
mical luminescence imaging, appropriate horseradish
peroxidase-conjugated secondary antibody was applied
(Amersham™, anti-rabbit, NA934V and ECL™kit, GE
Healthcare, RPN2106). Exactly 15 seconds of exposure
time was applied for each Oxyblot development. Based
on the identical expression setting and the same amount
of proteins applied on each Oxyblot experiment, the
fluorescent signal intensity was used to compare the
amount of oxidized protein level among different sam-
ples. The extent of overall protein oxidation of each sam-
ple was quantified using ImageJ http://rsbweb.nih.gov/ij.
For the statistical data evaluation, we first compared the
total protein oxidation extend of PINK1-KO to wild type
controls in each of the three brain regions (striatum,
midbrain and cortex) using Student’sT - t e s t .G i v e nt h e
lack of significant difference between PINK1-KO and
control, we combined values of these two groups
(PINK1-KO and control) of each mouse brain region,
and investigated protein oxidation level in regard to dif-
ferent brain regions. For this purpose, ANOVA was first
performed to detect among-group difference (p < 0.05),
whereas unpaired Student’s T-test was used subsequently
to assess between-group difference (p < 0.05).
2.7 Electron microscopy of mouse brain regions
For the electron microscopy of different brain regions,
cortex, striatum and substantia nigra (SN) tissue samples
of about one cubic mm of size were obtained from nor-
mal control mice (n = 3). Notice that we used substantia
nigra instead of the whole midbrain tissue, as this is the
most vulnerable region in PD pathology. Samples were
immediately submerged in 2.5% glutaraldehyde solution
in PBS for 16 hours. Electron microscopic analysis was
carried out on Epon embedded ultrathin tissue slides as
previously described [30,31]. The presences of total of
mitochondria, defective mitochondria (showing swelling
and disintegration of cistenea), mitochondria under mito-
phagic process (mitophagic vacuoles), as well as mito-
chondria under fission and/or fusion process were
quantified according to 30 random micrographs for each
tissue sample (magnification 3597 to 10, 000). Quantita-
tive data of total mitochondria, defective mitochondria
were assessed regarding to their numbers per cubic
micrometer [(μm^2)
-1]o no r i g i n a lt i s s u es a m p l e s .
Unpaired Student’s T-test was used to assess the statisti-
cal significance of the value in different brain regions.
3 Results
3.1 Number and identity of protein alterations in PINK1-
KO mice are brain region specific
Protein expression alterations induced by PINK1 knock-
out were accessed by the quantitative comparison of the
2DE patterns of PINK1-KO mice (n = 6) to normal con-
trol mice (n = 6) in three brain regions. In general, over
5000 protein spots could be detected on each of the 2DE
protein patterns. However, protein expression alterations
of each brain region in the PD mouse model were quite
unique respecting their isoelectric point and molecular
weight distribution (Figure 1). Among the three brain
regions investigated, the striatum tissue showed the high-
est overall number of protein expression alterations
(Table 1). Compared to wild type mice, 95 protein iso-
forms were up-regulated and 78 were down-regulated in
striatum of PINK1-KO mice. The total number of protein
alterations in striatum was over two-fold higher than in
the cortex and three-fold higher in regard to midbrain.
One hundred protein spots among these variant proteins
(58%) could be successfully identified with mass spectro-
metry. Unexpectedly, these protein spots were assigned
to merely 20 protein encoding genes. This suggests that
PINK1-KO induced protein alteration in striatum repre-
sents predominantly at the post translational modifica-
tion level. In midbrain tissue, which is the location of
substantia nigra, we detected a total of 62 protein spots
that were differentially expressed in PINK1-KO mice.
The majority of them (51) were down-regulated, whereas
11 protein isoforms were up-regulated. Out of these 62
protein spots, 57 (92%) could be identified, which yield
30 distinct protein encoding genes. In cortex tissue sam-
ples of the PINK1-KO mice, 75 protein spots were found
to be up-regulated while seven proteins were down-regu-
lated. Eighty-five percent (70/82) of these altered proteins
could be identified and were assigned to 28 non-redun-
dant gene symbols.
In a careful comparison of all three brain regions
respecting their protein expression alterations in PINK1-
KO mice, no single protein was observed to be altered in
all three brain regions. However, two proteins (Uchl1 and
Ckmt1) were co-changed in striatum and midbrain tissues
of PINK1-KO mice (although of bifurcated direction),
whereas five proteins were co-altered in striatum and cor-
tex tissues (Actg1, Gss, Ldhb, Taldo1 and Tpi1). When
comparing midbrain vs. cortex, three proteins showed
concomitant regulations. They are Aldoa, Gapdh and
Vdac1 (Figure 2). An overview of the number of identified
protein expression alterations in all three brain regions is
given in table 1.
3.2 PINK1 knockout exerted brain region specific impact
on mitochondrial proteins
Altered proteins in PINK1-KO mice were clustered
according to their functional involvement and cellular
localization. Respecting their cellular component identity,
the up-regulated proteins in PINK1-KO mouse brain tis-
sues were enriched in the GO-terms “mitochondrial
membrane” (p = 5.48e-05; Atp5c1, Ckmt1, Mdh2, Vdac1,
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1.23e-3; Actb, Actg1). The protein subsets of down-regu-
lated proteins in PINK1-KO showed enrichments in the
GO-terms “mitochondria” (p = 3.78e-08; Ldha, Cs, Got2,
Ak3, Vdac3, Pdhb, Mecr, Ckmt1, Gapdh, Etfa, Slc25a12,
Vdac1, Glod4, Mdh1).
Cellular functional involvement analysis on altered pro-
teins in PINK1-KO mice showed significant overrepre-
sentation of various energy metabolism pathways, with
partially divergent regulation directions in different brain
regions. KEGG pathways that bear significant overrepre-
sentation in altered proteins in PINK1-KO mice are
summarized in table 2. A common perturbed pathway in
all three brain regions is glycolysis and gluconeogenesis.
In cortex tissue of the PINK1-KO mice, six proteins
(Aldoa, Eno1, Gapdh, Ldhb, Pgk1 and Tpi1) belonging to
this pathway were up-regulated. In contrast, five proteins
participating in glycolysis and gluconeogenesis pathway
were down-regulated in the midbrain tissue of our PD
mouse model (Aldoa, Eno2, Gapdh, Ldha and Pdhb). In
addition, proteins of the Krebs cycle, which is down-
stream to glycolysis, showed increased expression in
striatum region of the PINK1-KO mice. Similarly, there
were indications that mitochondrial respiration chain
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Figure 1 Representative two-dimensional protein expression patterns of three different brain regions (striatum, midbrain and cortex)
showing significantly altered protein spots (blue circled, unpaired student T-test, n = 6, p < 0.05. Over 20% of expression alteration).
Over 5000 protein spots could be detected on each protein pattern. The gel insets demonstrate that there was little overlap of altered protein
isoforms among the three brain regions (gel images from PINK1-KO mice).
Table 1 Number of differentially expressed proteins and protein isoforms in striatum, midbrain and cortex tissues of
PINK1-KO mice compared to wild-type mice
Brain region Differentially expressed protein isoforms* Identified protein isoforms Number of corresponding genes
striatum 173 (95↑,7 8 ↓) 100 20
midbrain 62 (11↑,5 1 ↓)5 7 3 0
cortex 82 (75↑,7 ↓)7 0 2 8
Over 5000 protein spots were investigated (Student’s t-test, p < 0.05, changes over 20% vs. wildtype control).
*: ↑, up-regulated; ↓, down-regulated.
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but up-regulated in striatum and cortex. For example,
the electron transfer flavoprotein subunit alpha (Etfa)
was down-regulated in midbrain tissue of PINK1-KO
mice compared to that of wild type mice. In contrast, one
subunit of ATP synthase (Atp5c1) was drastically (2.2-
fold) up-regulated in cortex tissues of the PINK1-KO
mice. Apart from energy metabolism, we observed a con-
sistent down regulation of three protein isoforms of
mitochondrial channel protein Vdac1 and one isoform of
Vdac3 in the midbrain tissue of PINK1-KO mice. In con-
trast, Vdac1, the essential membrane potential keeper of
mitochondria, was 47% up-regulated in cortex tissue.
3.3 Cerebral cortex tissue showed higher basal and
dynamic levels of oxidative protection
Indications of selective oxidative protection were
observed among different brain regions in our mouse
bearing PINK1 loss-of-function. This was reflected
predominantly by the behavior of the cellular antioxi-
dant synthesizer glutathione synthetase (Gss). This
enzyme was 42% up-regulated in the striatum, and 24%
up-regulated in the cortex tissue of PINK1-KO mice.
Consistent with this finding, peroxiredoxin 1 (Prdx1)
protein was slightly up-regulated in cortex tissue of the
transgenic mice. In contrast, no change of these antioxi-
dant proteins was observed in midbrain tissues.
In order to detect the extent of oxidative damage in
mouse proteome, we employed a well established metho-
dology of redox proteomics on the 2DE gels (Figure 3A)
[32]. Contrary to our expectation, comparison of PINK1-
KO mouse to control samples respecting total amount of
oxidized proteins (protein carbonyls) revealed no signifi-
cant differences. However, when comparing the three
brain regions to each other, cerebral cortex tissue showed
a significantly lower degree (ca. 60%) of oxidized proteins
than midbrain or striatum. When using wild type mouse
striatum tissue as an internal reference (the mean value
0
Uchl1,
Ckmt1
Aldoa, Gapdh
Vdac1
Actg1, Gss, 
Ldhb, 
Taldo1, Tpi1
Striatum Midbrain
Cortex
Figure 2 Expression alteration overlaps among three brain regions in PINK1-KO mice were studied at the level of gene names.
Concomitant protein alterations were observed only between two brain regions at a time. The regulatory pattern of expression (up- or down-
regulation) was not taken into account.
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Page 6 of 18Table 2 Functional pathways (KEGG) that were overrepresented in PINK1-KO induced protein expression alterations of different brain regions
Up-regulated proteins in striatum:
KEGG pathway Number of proteins Multiple test adjusted p-value
Metabolic pathways Sucla2, Mdh2, Ckb, Gss, Idh2, Echs1, Ckmt1, Tpi1, Ldhb, Aldoc, Taldo1 2.66 e-13
Citrate cycle (TCA cycle) Sucla2, Mdh2, Idh2 4.02E-07
Propanoate metabolism Sucla2, Ldhb, Echs1 4.02E-07
Glycolysis/Gluconeogenesis Tpi1, Ldhb, Aldoc 1.42E-05
Down-regulated proteins in midbrain:
KEGG pathway Number of proteins Multiple test adjusted p-value
Metabolic pathways Ldha, Aldoa, Eno2, Pdhb, Mecr, Ckmt1, Suclg1, Gapdh, Pafah1b2, Mdh1 3.30 e-10
Glycolysis/Gluconeogenesis Gapdh, Ldha, Aldoa, Eno2, Pdhb 4.40E-09
Citrate cycle (TCA cycle) Suclg1, Pdhb, Mdh1 8.11E-07
Pyruvate metabolism Ldha, Pdhb, Mdh1 1.44E-06
Up-regulated proteins in cortex:
KEGG pathway Number of proteins Multiple test adjusted p-value
Metabolic pathways Cs, Auh, Aldoa, Gss, Abat, Atp5c1, Pgk1, Eno1, Tkt, Gapdh, Tpi1, Ldhb, Nme1, Got1, Taldo1 4.28E-18
Glycolysis/Gluconeogenesis Pgk1, Eno1, Gapdh, Tpi1, Ldhb, Aldoa 6.93E-11
Pentose phosphate pathway Tkt, Aldoa, Taldo1 1.55E-06
Regulation of actin cytoskeleton Actg1, Actb, Pfn1 3.00E-04
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8of which was set as 100%), the amount of oxidized pro-
teins in midbrain accounts 94.5% ± 19%. However, a sig-
nificant fewer amounts (40.4% ± 6%) of the proteins were
oxidized in cortex tissues compared to either midbrain
(p = 0.036) or striatum tissues (p = 0.024). As shown in
Figure 3B, this finding was obviously independent of the
PINK1 knockout.
3.4 Lack of feedback stimulation of alternative catabolic
programs in midbrain
Since the direct mode-of-action of PINK1 dysfunction is
the disturbance of cellular mitophagy, we set out to
investigate mitophagy-related protein expression altera-
tion as well as other catabolic processes in different brain
regions of PINK1-KO mice. In this respect, we observed
that the heat shock protein 70 (Hspa8), an important
player of chaperone-mediated autophagy, was signifi-
cantly up-regulated in cortex tissue, but not in striatum
or midbrain. Regarding cellular catabolic programs other
than autophagy, ubiquitin carboxy-terminal hydrolase L1
(Uchl1) was significantly down-regulated in midbrain,
but up-regulated in striatum tissue of the PINK1-KO
mice. Two other proteins that are involved in the ubiqui-
tination pathway were also significantly down-regulated
A)
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Figure 3 Immunostaining of protein carbonyl moieties revealed significantly lower amount of oxidized proteins in cortex tissue than
in striatum and midbrain in both PINK1-KO and wild type mice (ANOVA analysis followed by unpaired Student T-test, p < 0.05).A )A
representative Oxyblot image of a 2DE gel immunostained against protein carbonyls (image from PINK1-KO, midbrain). B) Bar chart showing
differential protein oxidation extents in striatum, midbrain and cortex tissues of PINK1-KO and control mice (mean ± SEM, n = 3. see Materials
and Methods for detail). Hereby, the average signal intensity of protein oxidation in striatum of control mice was set as 100%. Experiments were
repeated three times on exactly 100 μg of pooled protein extract of each brain region.
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Page 8 of 18Table 3 Detailed information regarding protein identification and expression pattern in striatum, midbrain and cortex tissues of the PINK1-KO (KO) mice in
respect to wildtype control mice (WT):
Striatum:
NCBI access
number
Gene
symbol
Number of
isoforms
Protein name Expression
ratio
(KO vs. wt)
T test
(p-value)
Mowse
score
Sequence
coverage
(%)
Number
of
matched
peptides
Molecular
weight
(Da)
Theoretical
pI
Functional annotation (KEGG pathway)
gi|6753428 Ckmt1 1 creatine kinase,
mitochondrial 1, ubiquitous
1.37 0.0002 235 12 5 46974 8.39 Metabolic pathways; Arginine and proline
metabolism
gi|6755929 Uchl1 7 ubiquitin carboxy-terminal
hydrolase L1
1.45 0.0008 67 47 9 24822 5.33 Parkinson’s disease
gi|3766201 Sucla2 4 ATP-specific succinyl-CoA
synthetase beta subunit
1.42 0.001 299 21 6 46215 5.65 Metabolic pathways; Citrate cycle (TCA
cycle); Propanoate metabolism;
gi|6678674 Ldhb 5 lactate dehydrogenase 2, B
chain
1.37 0.0012 136 51 2 36549 5.7 Metabolic pathways; Propanoate
metabolism; Glycolysis/Gluconeogenesis;
Pyruvate metabolism;
gi|31980844 Dhrs1 2 dehydrogenase/reductase
(SDR family) member 1
1.54 0.0016 395 21 7 33983 8.66
gi|10946574 Ckb 5 creatine kinase, brain 1.42 0.0018 465 25 8 42686 5.4 Metabolic pathways; Arginine and proline
metabolism
gi|112363107 Nefm 7 Neurofilament triplet M
protein
0.43 0.0025 56 12 2 95984 4.76 Amyotrophic lateral sclerosis (ALS)
gi|6680117 Gss 3 glutathione synthetase 1.42 0.0035 436 16 8 52214 5.56 Metabolic pathways; Glutathione
metabolism;
gi|15277976 Ndrg2 3 N-myc downstream
regulated gene 2
1.4 0.0046 93 6 2 40763 5.23
gi|809561 Actg1 4 gamma-actin 1.32 0.0048 84 5 2 40992 5.56 Regulation of actin cytoskeleton
gi|387422 Mdh2 8 malate dehydrogenase 1.37 0.0079 222 12 4 35588 8.93 Metabolic pathways; Citrate cycle (TCA
cycle); Pyruvate metabolism;
gi|14198249 Aldoc 4 Fructose-bisphosphate
aldolase C
1.34 0.0097 144 9 3 39307 6.47 Metabolic pathways; Glycolysis/
Gluconeogenesis; Pentose phosphate
pathway; Fructose and mannose
metabolism
gi|13097102 Ddah2 2 dimethylarginine
dimethylaminohydrolase 2
1.32 0.0098 183 18 4 29627 5.66
gi|33859640 Taldo1 3 transaldolase 1 1.34 0.0109 163 12 4 37363 6.57 Metabolic pathways; Pentose phosphate
pathway;
gi|6681195 Dlg4 4 postsynaptic density
protein 95
0.64 0.0133 38 4 2 80423 5.56 Huntington’s disease
gi|6753476 Cnp 1 cyclic nucleotide
phosphodiesterase 1
1.42 0.0142 371 21 8 47094 9.08
gi|27370516 Idh2 6 isocitrate dehydrogenase 2
(NADP+), mitochondrial
1.37 0.0151 221 10 4 50902 8.88 Metabolic pathways; Citrate cycle (TCA
cycle); Glutathione metabolism;
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8Table 3 Detailed information regarding protein identification and expression pattern in striatum, midbrain and cortex tissues of the PINK1-KO (KO) mice in
respect to wildtype control mice (WT): (Continued)
gi|54855 Tpi1 25 triosephosphate isomerase 1.36 0.0214 770 42 12 26679 6.9 Metabolic pathways; Glycolysis/
Gluconeogenesis; Fructose and mannose
metabolism;
gi|12805413 Echs1 2 Echs1 protein 1.31 0.0245 428 26 8 31237 8.76 Metabolic pathways; Propanoate
metabolism;
gi|7305485 Sh3gl1 4 SH3-domain GRB2-like 1 1.28 0.0307 136 7 3 41492 5.53 Endocytosis
Midbrain:
NCBI access
number
Gene
symbol
Number of
isoforms
Protein name Expression
ratio (KO
vs. wt)
Tt e s t
(p-value)
Mowse
score
Sequence
coverage
(%)
Number
of
matched
peptides
Molecular
weight
(Da)
Theoretical
pI
Functional annotation (KEGG pathway)
gi|13384652 Mecr 1 trans-2-enoyl-CoA
reductase, mitochondrial
precursor
0.53 0.001 88 4 2 40316 9.34 Metabolic pathways;
gi|6679937 Gapdh 3 similar to glyceraldehyde-3-
phosphate dehydrogenase
0.55 0.002 340 19 5 35787 8.44 Metabolic pathways; Glycolysis/
Gluconeogenesis;
gi|12849397 Glod4 1 Glyoxalase domain-
containing protein 4
0.69 0.003 545 46 11 33296 5.28
gi|6753428 Ckmt1 2 creatine kinase,
mitochondrial 1, ubiquitous
0.77 0.003 123 14 2 46974 8.39 Metabolic pathways;
gi|18017596 Snx4 1 sorting nexin 4 0.39 0.007 140 6 2 51745 5.58
gi|27369581 Slc25a12 1 solute carrier family 25
(mitochondrial carrier,
Aralar), member 12
0.46 0.007 318 9 5 74523 8.43
gi|21410877 Rap1gap 1 Rap1gap protein 0.72 0.007 62 9 2 45618 5.47
gi|387129 Mdh1 3 cytosolic malate
dehydrogenase
0.74 0.01 145 11 3 36454 6.16 Metabolic pathways; Citrate cycle (TCA
cycle); Pyruvate metabolism;
gi|33440467 Pafah1b2 2 Platelet-activating factor
acetylhydrolase, isoform 1b,
alpha2 subunit
0.72 0.015 91 8 2 25476 5.57 Metabolic pathways;
gi|21759113 Etfa 2 Electron transfer
flavoprotein subunit alpha,
mitochondrial precursor
(Alpha-ETF)
0.61 0.016 455 29 6 35018 8.42
gi|1915915 Ulip3 1 Ulip3 protein 0.73 0.016 177 12 3 62142 6.39
gi|31981086 Efhd2 3 EF hand domain containing
2
0.66 0.018 602 45 9 25084 5.07
gi|18606238 Gsn 1 gelsolin 0.7 0.018 328 9 5 80712 5.83 Regulation of actin cytoskeleton
gi|6671539 Aldoa 4 aldolase 1, A isoform 0.79 0.019 1158 59 17 39331 8.31 Metabolic pathways; Glycolysis/
Gluconeogenesis;
gi|6678483 Uba1 1 ubiquitin-activating enzyme
E1, Chr X
0.76 0.021 669 13 10 117734 5.43 Parkinson’s disease
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8Table 3 Detailed information regarding protein identification and expression pattern in striatum, midbrain and cortex tissues of the PINK1-KO (KO) mice in
respect to wildtype control mice (WT): (Continued)
gi|18152793 Pdhb 1 pyruvate dehydrogenase
(lipoamide) beta
0.78 0.021 497 32 11 38912 6.41 Metabolic pathways; Glycolysis/
Gluconeogenesis; Citrate cycle (TCA cycle);
Pyruvate metabolism;
gi|6755963 Vdac1 3 voltage-dependent anion
channel 1
0.66 0.0217 855 51 10 30737 8.62 Parkinson’s disease; Huntington’s disease;
Calcium signaling pathway
gi|6755967 Vdac3 1 voltage-dependent anion
channel 3
0.66 0.025 224 20 4 30733 8.96 Parkinson’s disease; Huntington’s disease;
Calcium signaling pathway
gi|2690302 Got2 2 aspartate aminotransferase
precursor
0.77 0.027 533 23 8 47382 9.05 Metabolic pathways; Alanine, aspartate and
glutamate metabolism
gi|11141704 Sir2L2 1 sirtuin 2 0.48 0.029 51 4 2 43244 8.22
gi|22902419 Gpd1l 2 glycerol-3-phosphate
dehydrogenase 1-like
0.48 0.029 61 4 2 42517 8.22 Glycerophospholipid metabolism
gi|7106301 Mapre1 1 microtubule-associated
protein, RP/EB family,
member 1
0.56 0.031 193 18 3 29997 5.12
gi|8567410 Syn2 1 synapsin II 0.61 0.034 70 3 2 52418 7.62
gi|6671569 Arbp 2 acidic ribosomal
phosphoprotein P0
1.41 0.037 196 19 4 34195 5.91
gi|9845299 Suclg1 1 succinate-CoA ligase, GDP-
forming, alpha subunit
1.21 0.039 88 9 2 34953 9.45 Metabolic pathways; Citrate cycle (TCA
cycle); Propanoate metabolism
gi|61098212 Uchl1 1 ubiquitin carboxy-terminal
hydrolase L1
0.65 0.04 157 16 3 24822 5.14 Parkinson’s disease
gi|6754524 Ldha 6 lactate dehydrogenase 1, A
chain
0.61 0.046 151 14 3 36475 7.62 Metabolic pathways; Glycolysis/
Gluconeogenesis; Pyruvate metabolism;
Propanoate metabolism
gi|29789104 Napb 1 N-ethylmaleimide sensitive
fusion protein attachment
protein beta
0.76 0.046 708 42 10 33536 6.41
gi|7305027 Eno2 4 enolase 2, gamma neuronal 0.69 0.047 861 43 13 47267 4.99 Metabolic pathways; Glycolysis/
Gluconeogenesis;
gi|55931021 Gdi2 3 Gdi2 protein 1.64 0.049 158 13 3 50506 5.93
Cortex:
NCBI access
number
Gene
symbol
Number of
Isoforms
Protein name Expression
ratio (KO
vs. wt)
T test
(p-value)
Mowse
score
Sequence
coverage
(%)
Number
of
matched
peptides
Molecular
weight
(Da)
Theoretical
pI
Functional annotation (KEGG pathway)
gi|4760600 Ak3 1 adenylate kinase isozyme 3 0.66 0.0004 124 47 11 24625 8.57
gi|13385942 Cs 5 citrate synthase 0.74 0.0057 130 28 16 51703 8.72 Metabolic pathways;
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8Table 3 Detailed information regarding protein identification and expression pattern in striatum, midbrain and cortex tissues of the PINK1-KO (KO) mice in
respect to wildtype control mice (WT): (Continued)
gi|37700232 Nme1 4 nucleoside-diphosphate
kinase 1
1.22 0.0006 91 48 9 17197 6.84 Metabolic pathways;
gi|19547889 Gss 3 glutathione synthetase 1.24 0.0386 107 26 12 51913 6.52 Metabolic pathways;
gi|42542422 Hspa8 5 Heat shock protein 8 1.24 0.0019 180 35 23 68074 5.32
gi|123230136 Prdx1 1 peroxiredoxin 1 1.24 0.0228 64 23 5 18915 6.82
gi|37202121 Abat 3 4-aminobutyrate
aminotransferase
1.25 0.0005 227 37 24 56416 8.35 Metabolic pathways; Alanine, aspartate and
glutamate metabolism; Propanoate
metabolism; Valine, leucine and isoleucine
degradation
gi|113680348 Fscn1 2 fascin homolog 1, actin
bundling protein
1.26 0.0017 168 42 17 54474 6.44
gi|34784434 Eno1 4 Eno1 protein 1.26 0.0062 139 43 16 39757 5.86 Metabolic pathways; Glycolysis/
Gluconeogenesis;
gi|56789289 Ldhb 4 Ldhb protein 1.27 0.0011 86 42 7 11317 5.73 Metabolic pathways; Glycolysis/
Gluconeogenesis; Propanoate metabolism;
Cysteine and methionine metabolism
gi|6679439 Ppia 4 peptidylprolyl isomerase A 1.3 0.0006 99 53 12 17960 7.74
gi|6755040 Pfn1 3 profilin 1 1.31 0.0022 176 73 14 14948 8.46 Regulation of actin cytoskeleton
gi|6678469 Tuba1c 2 tubulin, alpha 1C 1.32 0.0000088 98 35 13 49877 4.96
gi|809561 3 1 gamma-actin 1.32 0.0028 230 56 24 41724 5.3 Regulation of actin cytoskeleton
gi|6679937 Gapdh 6 glyceraldehyde-3-
phosphate dehydrogenase
1.33 0.0005 211 60 23 35787 8.44 Metabolic pathways; Glycolysis/
Gluconeogenesis;
gi|49868 Actb 2 beta-actin (aa 27-375) 1.35 0.0019 237 54 27 39161 5.79 Regulation of actin cytoskeleton
gi|148686116 Taldo1 2 transaldolase 1, isoform
CRA_e
1.39 0.0008 156 51 18 31514 7.66 Metabolic pathways; Pentose phosphate
pathway
gi|6678413 Tpi1 1 triosephosphate isomerase
1
1.39 0.0006 147 42 9 26696 6.9 Metabolic pathways; Glycolysis/
Gluconeogenesis; Fructose and mannose
metabolism
gi|123210063 — 1 novel protein 1.44 0.0009 38 20 4 24445 8.76
gi|6755963 Vdac1 1 voltage-dependent anion
channel 1
1.47 0.0019 161 62 15 30737 8.62
gi|6671539 Aldoa 4 aldolase 1, A isoform 1.52 0.005 179 43 17 39331 8.31 Metabolic pathways; Glycolysis/
Gluconeogenesis; Pentose phosphate
pathway; Fructose and mannose
metabolism
gi|1915915 Dpysl1 2 Ulip3 protein 1.56 0.0058 225 40 24 62142 6.39
gi|20072952 Auh 2 Auh protein 1.62 0.000068 114 32 13 32621 9.57 Metabolic pathways; Valine, leucine and
isoleucine degradation
gi|11066098 Tkt 1 transketolase 1.89 0.0058 65 26 11 60545 6.54 Metabolic pathways; Pentose phosphate
pathway;
D
i
e
d
r
i
c
h
e
t
a
l
.
P
r
o
t
e
o
m
e
S
c
i
e
n
c
e
2
0
1
1
,
9
:
5
9
h
t
t
p
:
/
/
w
w
w
.
p
r
o
t
e
o
m
e
s
c
i
.
c
o
m
/
c
o
n
t
e
n
t
/
9
/
1
/
5
9
P
a
g
e
1
2
o
f
1
8Table 3 Detailed information regarding protein identification and expression pattern in striatum, midbrain and cortex tissues of the PINK1-KO (KO) mice in
respect to wildtype control mice (WT): (Continued)
gi|21311871 Nebl 1 nebulette 2.2 0.0007 74 40 13 31093 8.54
gi|163838648 Atp5c1 1 ATP synthase, H+
transporting, mitochondrial
F1 complex, gamma
subunit isoform b
2.2 0.0007 126 42 15 30237 8.86 Metabolic pathways;
gi|202423 Pgk1 2 (with
divergent
regulation)
phosphoglycerate kinase 1.54; 0.77 5.00E-03;
1.22E-02
265 58 28 44522 8.02 Metabolic pathways; Glycolysis/
Gluconeogenesis;
gi|160298209 Got1 2 (with
divergent
regulation)
glutamate oxaloacetate
transaminase 1, soluble
1.62; 0.78 1.12E-02;
2.60E-03
130 30 12 46219 6.68 Metabolic pathways; Alanine, aspartate and
glutamate metabolism
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8in midbrain (Uba1, Ulip3). Contrary to this, two isoforms
of the Ulip3 protein were observed to be up-regulated in
the cerebral cortex tissue of PINK1-KO mice. Notably,
no up-regulation of such catabolic process related
proteins was observed in midbrain tissues of the PD
mouse model.
Detailed information regarding protein identification
and expression pattern is provided in Table 3.
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Total mitochondria
Mitophagy vacuole
Defective mitochondria
P=0.008
**
Figure 4 Electron microscopy revealed higher incidences of mitophagic vacuoles in cortex tissue of wild type mouse (designated as
** in figure. ANOVA test followed by unpaired student T-test, n = 30 for each brain region, p < 0.05). A) Insets of electron micrographs
highlighting typical mitophagic vacuoles (arrow heads) that contain mitochondria and other cargos found in the cortex, striatum and substantia
nigra. B) Bar chart showing the number of total mitochondria, mitophagic vacuoles and defective mitochondria in three mouse brain regions
investigated (mean ± SEM). The cortex, striatum and substantia nigra (the most vulnerable area of midbrain in PD pathology) samples of three
wild type mice were used for the electron microscopy investigation. Thirty micrographs were inspected for each tissue sample.
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Page 14 of 183.5 Brain region specific mitophagy capacity in wild type
mice
In order to in-depth scrutinize the notion of fundamental
differential mitophagy performance in different mouse
brain regions, we carried out a cellular ultra-structural
examination to quantify the number of mitochondria
undergoing mitophagy. Therei sn od i f f e r e n c ei ne i t h e r
the total number of mitochondria (Figure 4A), or the
number of mitochondria under fission or fusion among
three brain regions investigated (data not shown). How-
ever, our histological examination using electron micro-
scopy showed that a considerably higher amount of
mitochondria were undergoing the process of mitophagy
in normal mouse cortex tissue (2.28 ± 0.82 per μm^2)
compared to normal striatum (0.85 ± 0.33 per μm^2, p =
0.009). The level of mitochondria undergoing mitophagy
in cortex was also significantlyh i g h e rt h a ni ns u b s t a n t i a
nigra (0.98 ± 0.39 per μm^2, p = 0.029). Moreover, com-
pared to striatum, we observed significantly higher num-
ber of defective mitochondria in substantia nigra (2.05 ±
0.86 in SN vs. 0.98 ± 0.4 per μm^2 in striatum,
p = 0.008). Figure 4 demonstrate the representative
micrograph of cortex (7750×) showing recurrent inci-
dences of mitophagic issue in all three wild type mouse
brain regions.
4 Discussion
The manifestation of Parkinson’s disease (PD) is initiated
by a selective loss of dopaminergic neurons in the sub-
stantia nigra pars compacta (SN), a core complex in the
midbrain. As dopamine is physiologically transported
from the substantia nigra to the striatum by dopaminer-
gic projections, this leads to a lack of dopamine in the
striatum, which in turn causes prominent motor function
: PINK1
: proteolytic cleavage of PINK1
Vdac1 : Voltage-dependent anion-selective channel protein 1 
ǻȥm         : Decrease of mitochondrial membrane potential
Pink1
Vdac1
Intact mitochondria
Pink1
Parkin
ǻȥm        
Defective mitochondria
Mitophagy
Vdac1
Figure 5 Hypothetic mechanism of PINK1-Parkin mediated mitophagy according to the hypothesis raised by Narendra [20,42]. The
cellular mitochondria are governed by the quality control mechanism mitophagy, a form of autophagy in which defective mitochondria are
selectively degraded by trafficking to lysosome. Left: PINK1 is a mitochondria located protein kinase with its enzymatic domain facing the
cytosol. Expression of PINK1 on individual mitochondria is negatively regulated by Vdac1-dependent proteolysis to maintain low levels of PINK1
protein on intact mitochondria. Right: Loss of mitochondrial membrane potential (ΔΨm ⇓) leads to the accumulation of PINK1 on mitochondria.
This gives Parkin the signal to recruit the PINK1-flagged mitochondria for mitophagy. This recruitment leads to the clearance of the defective
organelle through the autophagosome formation.
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Page 15 of 18disturbances [1]. In a sense, understanding of the selec-
tive vulnerability of dopamine neuron in substantia nigra
could shed light on potential clues for PD therapeutic
concept.
Emerging evidences have been strengthening the link
between the integrity of the neuronal mitochondria to
PD. Here, mitophagy, a form of autophagy for selective
degradation of defective mitochondria represent one of
the key aspects [33,34]. As a major player in mitophagy
mechanism, PINK1 is a mitochondrial protein kinase
with its enzymatic domain facing the cytosol [14].
According to the hypotheses of Narendra and others,
expression of PINK1 on individual mitochondria is nega-
tively regulated by Vdac1-dependent proteolysis to main-
tain low levels of PINK1 protein on intact mitochondria
(Figure 5, left). Loss of mitochondrial membrane poten-
tial, characterized by the Vdac1-downregulation, leads to
the accumulation of PINK1 on mitochondria. This gives
Parkin the signal to recruit the PINK1-flagged mitochon-
dria to autophagosome for degradation (Figure 5) [20,35].
As typical post-mitotic cells, the neurons cannot distri-
bute their damaged components to daughter cells, whereas
cell death is unfavorable regarding tissue function [36].
This unique aspect of the neuron makes the finding of
mitophagy-based cellular maintenance especially revealing
concerning brain function perseverance [33]. Nevertheless,
question remains regarding the formation of brain region
specific neuronal loss in PD. With our current experimen-
tal setup, we aimed to interrogate the possible link
between mitophagy functionality and the selective neuro-
nal vulnerability in PD.
Among the available Parkinson’s disease animal mod-
els, the mouse model with a loss-of-function mutation in
PINK1 offers the most obvious link between mitophagy
dysfunction and PD [21]. Unlike some other PD mouse
models, the PINK1-KO mouse does not show dopami-
nergic neuron death. This was mirrored in our study by a
missing observation of difference of oxidized protein
levels in PINK1-KO in comparison to control. However,
previous works have shown that loss of PINK1 causes
clear-cut mitochondrial dysfunction and increased sensi-
tivity of the neurons to oxidative stress, presumably
through the blockage of mitophagy [21]. In the current
study, different extents of proteomic shift was observed
in different brain regions of our PD model, the PINK1-
KO mice, with very little overlaps of protein expression
alterations among brain regions. This reiterates the issue
of brain region specificity in PD progression. Specifically,
midbrain of PINK1-KO mice showed the highest number
of non-redundant protein alterations. This correlates well
with the higher vulnerability of this brain region that is
specific for PD pathology.
Furthermore, our protein functional categorizations
showed that there were significant down regulations of
diverse mitochondrial energy metabolism pathways in
the midbrain upon PINK1-KO (glycolysis, gluconeogen-
esis, pentose pathway, Krebs cycle, respiratory chain
function). Lowered energy level can be considered as a
general correlate to the accumulation of depolarized
mitochondria, which is again associated with heightened
oxidative stress [31,37].
We next investigated the oxidative protein damage pat-
terns in three distinct brain regions with and without
PINK1-KO. Our redox proteomic analysis showed that the
cortex tissue was subjected to less extent of overall protein
oxidative damage at both basal (wild type) and dynamic
(under PINK1-KO) level: On the one hand, the Oxyblot
staining experiments demonstrated minor extent of oxida-
tive damage in the cortex tissue irrespective to the trans-
gene. On the other hand, higher oxidative defense in
cerebral cortex region was mirrored by the up-regulation
of antioxidant-related proteins in our PD mouse model
(glutathione synthetase and peroxiredoxin 1). Gluthatione
is considered as the most important intracellular antioxi-
dant. Upon the lack of glutathion, highly toxic hydroxyl
radicals (OH·) will be generated though Fenton reaction.
In sequence with this, the feedback up-regulation of
glutathione synthetase has been considered as one of the
earliest detectable changes in presymptomatic PD develop-
ment [38]. Under the insult of PINK1-KO, higher expres-
sion of the oxidative protection protein glutathione
synthetase was observed in cortex and striatum tissues of
the PINK1-KO mice. Importantly, such phenomenon was
not observed in midbrain tissues. Together, our results
suggest that cortex, and to a lesser extent striatum, could
be better protected against oxidative damage.
Most intrinsically, the observed drastically reduced
Vdac1 protein level in midbrain tissue of the PINK1-KO
mice offer us signs of the loss of mitochondrial mem-
brane potential in the midbrain of PINK1-KO mice.
Remarkably, this phenomenon was absent in striatum,
whereas an up-regulation of Vdac1 proteins was observed
in cortex tissue under PINK1-KO, which could indicate
certain compensation mechanism in cortex tissues upon
PINK1-KO. Drastically reduced Vdac1 protein level in
midbrain tissue of the PD mouse model could reflect the
brain region specific depolarization of mitochondria in
PINK1-KO mice. Although such speculation would need
direct investigations on mitochondrial membrane poten-
tial, this could suggest that mitophagy dysfunction
induced by PINK1-KO led to a severe accumulation of
non-potentiated mitochondria predominantly in the mid-
brain tissue [39].
To test this hypothesis of “built-in” brain-region specific
mitophagy capacity in mouse, we conducted an electron
microscopy study on wild type mice. Here, the normal
mouse cortex tissue showed a 60% higher occurrence of
mitophagic vacuoles compared to substantia nigra,
Diedrich et al. Proteome Science 2011, 9:59
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Page 16 of 18whereas the amount of mitophagic vacuoles in striatum
was comparable to that of substantia nigra.E v e nm o r e
notably, SN indeed contained intrinsically higher number
of defective mitochondria in comparison to striatum.
These observations ultimately validate the intrinsic differ-
ential mitophagic capacity in different brain regions.
The fact that PINK1 knockout induced mitophagy dis-
turbance did not adversely influence the cortex and stria-
tum tissues in terms of mitochondrial energy metabolism
suggests some compensatory mechanism regarding cellu-
lar maintenance. In this respect, recent reports showed
that autophagy and ubiquitination/proteasome pathways
are two closely interwired cellular catabolic machineries
[40,41]. We observed that two ubiqitination-related pro-
teins were up-regulated in cortex and striatum tissues
after PINK1-KO-induced mitophagy dysfunction. This
implies that cortex and striatum tissues were able to
respond to the mitophagy failure by stimulating the ubi-
quitin pathway as alternative catabolic mechanism,
whereas midbrain did not. In the same scenario, the heat
shock protein 70 (Hspa8), an important mediator of cha-
perone-mediated autophagy, was significantly up-regu-
lated in cortex tissue, but not in striatum or midbrain
under PINK1-KO. Together, this prompted us to suspect
that the cerebral cortex tissue can compensate for mito-
phagic failure by stimulation of alternative catabolic pro-
cess to rid the cell from oxidized proteins. Such
capability could have increased the robustness of cortex
tissue against oxidative damage.
I ns u m m a r y ,u s i n gt h eP I N K - K Om o u s ea sam o d e l ,
our hypothesis advanced in this work is that selective
neuron vulnerability in Parkinson’sd i s e a s ec o u l db ec o -
determined by differential mitophagy capacity, differen-
tial oxidative protection, as well as differential feedback
stimulation of alternative catabolic mechanisms in dis-
tinct brain regions. Our 2D-DIGE based study provides a
starting point towards such advanced hypothesis, which
will need to be scrutinized by subsequent investigations
on mitochondrial membrane potential, metabolism func-
tions and most importantly, direct studies on compre-
hensive mitotophagy pathway.
Abbreviations
2DE: two-dimensional protein electrophoresis; 2D-DIGE: two dimensional
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